TrialLineage Case
Daraxonrasib in pancreatic cancer
This page traces a pancreatic cancer drug story backward through the scientific lineage that made it possible. It is designed to be read in layers: a plain-language summary for any reader, a visual map of the discovery chain, a timeline of milestones and detours, and a deeper explainer for those who want the fuller scientific history.
In plain language
What is this case about?
Daraxonrasib is a drug being tested in clinical trials for pancreatic cancer. It is designed to block a specific protein called KRAS, which is found in a mutated form in most pancreatic tumors. When KRAS is mutated, it gets stuck in an “on” position and keeps telling the cell to grow — even when the cell should stop. That relentless growth signal is one of the core reasons pancreatic cancer is so aggressive and hard to treat.
Pancreatic cancer matters because it is one of the deadliest forms of cancer. It is usually diagnosed late, it resists most existing treatments, and survival rates have improved only slowly over decades. A drug that could effectively target the molecular driver behind the disease would represent a genuine shift in how the disease is treated.
But daraxonrasib did not appear out of nowhere. It exists because of a long chain of earlier scientific work — decades of research across multiple fields that gradually built the understanding, tools, and chemical strategies needed to reach this point. This page traces that chain.
At a glance
- The drug: daraxonrasib, a KRAS-directed therapy now in human trials
- The disease: pancreatic cancer — aggressive, usually late-diagnosed, with limited effective treatments
- The target: KRAS, a protein that acts as a growth switch inside cells and is mutated in most pancreatic cancers
- The timeline: KRAS was identified as a cancer gene in the early 1980s — it took roughly four decades to develop credible drugs against it
- Why it took so long: the protein’s shape and behavior made it extremely difficult to target with conventional drug-design strategies
What had to happen first?
Five steps that made this drug possible
None of these steps alone produced a drug. Each one built on the last, and the full chain took decades to assemble.
1
Find the gene
Scientists discovered that certain genes, when altered, can drive cells to become cancerous. KRAS was one of the first identified.
2
Understand the wiring
Researchers mapped the signaling pathway KRAS belongs to and learned how a mutation locks it into constant activity.
3
Connect it to the disease
Studies showed that KRAS mutations appear in nearly all pancreatic cancers and are present from the earliest stages.
4
Learn how to reach it
Structural and chemical biology gradually revealed the protein’s shape, behavior, and potential vulnerabilities.
5
Design and test a drug
Medicinal chemists built compounds to target KRAS, and clinical teams designed trials to test them in patients.
Reverse-lineage map
How this trial traces back through science
Read from top to bottom to see the chain of scientific fields that built on each other. Side branches show where the path diverged, where ideas failed but still mattered, and where enabling methods made later steps possible.
Branch point
Viral vs. cellular origin debate
Were cancer genes viral or cellular? The answer — cellular — reshaped the entire field.
Failed approach
EGFR inhibitors in KRAS-mutant tumors
Blocking receptors upstream of KRAS failed because the switch no longer depended on external signals.
Failed approach
Farnesyltransferase inhibitors
Tried to block KRAS from reaching the cell membrane. RAS used alternate routes.
Clinical trial
Daraxonrasib in human patients
Translational step
Translational oncology
Chemistry
Medicinal chemistry
Structural era
Chemical & structural biology
Disease research
Pancreatic cancer biology
Cell biology
Protein signaling biology
Basic science
Oncogene discovery
Branch point
Biomarker-selected vs. all-comers trials
Should trials enroll broadly or select for KRAS mutations? Selection became essential.
Enabling method
Covalent drug design
New chemical strategies allowed drugs to form permanent bonds with KRAS — a key technical advance.
Branch point
Direct inhibition vs. synthetic lethality
Two divergent strategies for KRAS-mutant cancers. Both remain active research directions.
Enabling method
X-ray crystallography and cryo-EM
Structural methods revealed binding pockets on KRAS that were invisible to earlier techniques.
Branch point
Viral vs. cellular origin debate
Were cancer genes viral or cellular? The answer — cellular — reshaped the entire field.
Branch point
Biomarker-selected vs. all-comers trials
Should trials enroll broadly or select for KRAS mutations? Selection became essential.
Failed approach
EGFR inhibitors in KRAS-mutant tumors
Blocking receptors upstream of KRAS failed because the switch no longer depended on external signals.
Failed approach
Farnesyltransferase inhibitors
Tried to block KRAS from reaching the cell membrane. RAS used alternate routes.
Enabling method
Covalent drug design
New chemical strategies allowed drugs to form permanent bonds with KRAS — a key technical advance.
Branch point
Direct inhibition vs. synthetic lethality
Two divergent strategies for KRAS-mutant cancers. Both remain active research directions.
Enabling method
X-ray crystallography and cryo-EM
Structural methods revealed binding pockets on KRAS that were invisible to earlier techniques.
Discovery timeline
Key moments in the path to daraxonrasib
This timeline traces milestones, branch points, detours, and convergence events across the scientific fields that eventually produced a KRAS-directed drug in pancreatic cancer trials. Not every entry is a success — several represent failures or unresolved debates that still shaped what came next.
Retroviral oncogenes are identified
Peyton Rous had shown decades earlier that a virus could cause cancer in chickens, but it was the work of J. Michael Bishop and Harold Varmus at UC San Francisco that transformed the field. Their lab demonstrated that the cancer-causing gene carried by the Rous sarcoma virus — src — was not a viral invention but a captured version of a normal cellular gene. This insight, which earned them the 1989 Nobel Prize, established the principle that the cell’s own genes could become oncogenic.
Human cellular oncogenes are confirmed
Robert Weinberg’s laboratory at the Whitehead Institute (MIT), along with Michael Wigler’s group at Cold Spring Harbor Laboratory and Mariano Barbacid’s team at the NCI, independently demonstrated that DNA from human tumor cells could transform normal cells in culture. The responsible genes turned out to be mutated versions of RAS — the same gene family found in retroviruses. Cancer was now provably a disease of the cell’s own altered genes.
The viral vs. cellular origin debate resolves
The Bishop–Varmus discovery and the Weinberg–Wigler–Barbacid transfection experiments converged on the same conclusion: oncogenes are cellular in origin. This settled a decades-long debate and redirected enormous research effort away from viral causation theories and toward understanding how the cell’s own genetic programs could become drivers of disease.
KRAS is identified as a human oncogene
The Barbacid, Weinberg, and Wigler laboratories each identified activated RAS genes in human tumors. Specific point mutations in HRAS were pinpointed first, followed quickly by KRAS and NRAS. Channing Der and Geoffrey Cooper also contributed key early characterizations. Together, these groups established the RAS family as the most frequently mutated oncogene family in human cancer — a status it still holds.
The RAS-MAPK signaling pathway is mapped
Research groups across cell biology and biochemistry — including work by investigators such as Chris Marshall (Institute of Cancer Research, London), Melanie Cobb (UT Southwestern), and others in the growing signal transduction community — charted the cascade downstream of RAS. They showed that active RAS recruits RAF kinase, which activates MEK, which activates ERK, relaying the growth signal to the nucleus. This chain explained how a single stuck switch could reprogram an entire cell.
KRAS mutations found in most pancreatic cancers
Ralph Hruban, Scott Kern, Bert Vogelstein, and other pathologists and molecular biologists at Johns Hopkins demonstrated that KRAS mutations appear in roughly 90% of pancreatic ductal adenocarcinomas and are detectable in early precursor lesions called PanINs. Earlier work by Almoguera and colleagues had first reported KRAS mutations in pancreatic tumors in 1988. Together, these findings established KRAS as not just common in the disease but present from its earliest origins — making it the most biologically central target, and one of the hardest to reach.
KRAS is labeled “undruggable”
The protein’s small size, smooth surface, and picomolar affinity for GTP made it resist every conventional drug-design approach that pharmaceutical and academic labs attempted. The NCI’s RAS Initiative, launched later to address this problem directly, reflected how deeply the field had accepted the difficulty. For roughly two decades, much of the research community treated direct KRAS inhibition as infeasible and redirected effort toward downstream or indirect strategies.
Farnesyltransferase inhibitors fail in clinical trials
One of the first major pharmaceutical efforts to target RAS — pursued by companies including Johnson & Johnson (tipifarnib) and Schering-Plough (lonafarnib) — aimed to block the enzyme that attaches RAS to the cell membrane. The biological logic was sound, but KRAS could use an alternative enzyme (geranylgeranyltransferase) to reach the membrane. Clinical trials failed. The experience taught the field that RAS biology was more redundant than expected.
Downstream-only strategies show limited benefit in KRAS-mutant tumors
Because KRAS itself seemed untouchable, researchers targeted downstream kinases — RAF, MEK, ERK. RAF inhibitors (such as vemurafenib, developed with contributions from the Bollag group at Plexxikon) worked well in BRAF-mutant melanoma but paradoxically activated the pathway in KRAS-mutant cells. MEK inhibitors showed modest single-agent activity. Blocking one downstream branch often triggered compensatory signaling through parallel pathways. The network was more resilient than a simple chain model predicted.
EGFR-targeted drugs fail in KRAS-mutant patients
Drugs targeting EGFR — including cetuximab and erlotinib, developed with early contributions from John Mendelsohn (MD Anderson) and others — were tested broadly. In colorectal and lung cancers, KRAS mutation status emerged as a negative predictor of response: patients with KRAS-mutant tumors did not benefit. The growth signal originated from the stuck switch inside the cell, making upstream receptor blockade irrelevant.
Structural biology reveals hidden vulnerabilities on KRAS
Kevan Shokat’s laboratory at UC San Francisco made a pivotal discovery: using crystallography, they identified a previously unrecognized pocket on the surface of KRAS G12C that was accessible only when the protein was in its inactive (GDP-bound) state. This pocket, called the switch-II pocket, became the first credible site for direct covalent inhibition. The finding was enabled by advances in X-ray crystallography and later cryo-electron microscopy across multiple structural biology groups.
Direct inhibition vs. synthetic lethality — two paths diverge
With the Shokat lab’s structural breakthrough, one branch of research pursued direct covalent inhibitors of KRAS. Another branch, driven by groups including those of William Hahn (Broad Institute) and others working on genetic dependency screens, explored synthetic lethality — killing KRAS-mutant cells by targeting something else they uniquely depend on. Both branches remain active in clinical research, and neither has fully displaced the other.
Covalent inhibitors demonstrate proof of concept against KRAS
Building on the Shokat lab’s foundational chemistry, teams at Amgen (developing sotorasib) and Mirati Therapeutics (developing adagrasib) advanced covalent KRAS G12C inhibitors into clinical testing. These compounds demonstrated for the first time that KRAS could be directly, selectively, and safely inhibited in human patients. The “undruggable” label lost its authority. The broader RAS drug-discovery community — including the NCI RAS Initiative — continued to expand efforts to additional KRAS mutation subtypes beyond G12C.
Translational oncology connects lab evidence to trial design
Translational research groups at academic cancer centers and industry sponsors bridged the gap between laboratory findings and clinical feasibility. They established biomarker-selection strategies using next-generation sequencing, defined patient populations by specific KRAS mutation subtype, and designed dose-escalation and expansion protocols that reflected the pharmacology of KRAS-directed compounds.
Daraxonrasib enters clinical trials in pancreatic cancer
The full chain converges: Bishop and Varmus established that oncogenes are cellular, Weinberg and others identified RAS mutations in human tumors, signaling biologists mapped the pathway, pancreatic cancer researchers showed KRAS was central to the disease, Shokat’s lab found a druggable pocket, industry chemists built compounds that reached it, and translational teams designed trials to test the drug in the patients most likely to benefit. Daraxonrasib is one product of that decades-long chain.
Why this case matters
Daraxonrasib is important not just because it represents a new therapeutic effort in pancreatic cancer, but because it stands on decades of inquiry into how cancer genes work, how KRAS signals, why pancreatic tumors depend so heavily on KRAS-related biology, and how chemistry gradually found ways to intervene. In public language, this is not just a story about one drug. It is a story about how many layers of science had to accumulate before a treatment strategy could become plausible in humans.
Why earlier layers matter
This case shows how human disease breakthroughs often depend on many layers of scientific work that do not look directly therapeutic at the time they are performed. The public usually sees the late-stage milestone. TrialLineage is designed to make the earlier layers visible.
Failed or indirect paths still mattered
Not every line of inquiry produced a successful therapy. But many of those routes still clarified the biology, exposed weaknesses in old assumptions, and improved the field’s ability to design better strategies later.
Deep-dive view
The longer scientific lineage
Each section below expands on one layer of the discovery chain. For readers who want the fuller history behind the visual map above.
1. Cancer had to become molecular
One of the deepest roots of this case is the shift from thinking of cancer as vague uncontrolled growth to understanding it as a disease that can be driven by altered genes and signaling pathways. That change created the conceptual framework for targets like KRAS to matter at all.
2. KRAS had to be understood as a signaling switch
Scientists then had to work out what KRAS actually does. In lay terms, it acts like part of the cell’s growth-control wiring. When mutated, that wiring can remain abnormally active. That helped explain why KRAS is not just associated with cancer, but functionally important to it.
3. Pancreatic cancer biology showed the target was central
Pancreatic cancer research gradually showed that KRAS-related biology is deeply woven into the disease. That gave the field a reason to keep trying, even when direct targeting looked very difficult.
4. The “undruggable” era still produced useful knowledge
For years, KRAS was treated as an extremely hard target. But those frustrating years still mattered. Researchers learned about protein shape, signaling dependencies, pathway behavior, and why earlier strategies struggled. Even indirect or unsuccessful routes helped narrow the path toward better ones.
5. Chemistry and structure changed the odds
Chemical biology, structural biology, and medicinal chemistry helped transform a biological problem into a tractable drug discovery problem. The field moved from knowing KRAS mattered to understanding how drug design might actually engage it.
6. Human trials turned scientific possibility into evidence
Once a credible candidate exists, the story becomes clinical as well as scientific. Trial design, patient selection, outcome measures, safety, and comparison against existing care all become part of the lineage of whether an idea truly matters in human disease.
Related concept pages
Offshoot explanations this case connects to
Each concept below represents a connected background field that helped make the daraxonrasib trial possible. Pages that are live can be read as standalone explainers or as companions to this case.
About this page
This is a TrialLineage case page. It traces a human-disease trial backward through the scientific lineage that made it possible, presented in four layers: a plain-language summary for any reader, a visual reverse-lineage map showing main paths and side branches, a discovery timeline of milestones, branch points, detours, and convergence events, and a deeper explainer for those who want the fuller scientific history. The format is designed to make the discovery process behind phase 1–3 trials visible and understandable.